GSK3B and Alzheimer disease: Extensive in vitro studies are warranted to define the specific molecular interactions between these compounds and targets such as COX-2 and GSK-3β, while in vivo research should explore their pharmacokinetics, bioavailability, and neuroprotective potential in AD models.